Lawson Wulsin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lawson Wulsin has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Eugene Somoza
University of Cincinnati and Psychiatry Service, VA Medical Center
2 shared publicationsJeffery Heck
UNIVERSITY OF NORTH CAROLINA, ASHEVILLE
2 shared publicationsAaron Pinkhasov
NYU Winthrop Hospital, Stony Brook School of Medicine, New York, United States of America
1 shared publicationAlan Storrow
1 shared publicationAllison Smith
Medical University of South Carolina, United States of America
1 shared publicationAmit J. Shah
1 shared publication
Latest Publications
- 15 October 2022
- Published by Springer Nature
- p. 525-540
Negative Emotions: Depression, Exhaustion, and Anxiety
- 15 October 2022
- Published by Springer Nature
- p. 525-540
Negative Emotions: Depression, Exhaustion, and Anxiety
- 24 January 2022
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 84 (3) , 267-275
Stress Measurement in Primary Care: Conceptual Issues, Barriers, Resources, and Recommendations for Study
Objective: Exposure to stressors in daily life and dysregulated stress responses are associated with increased risk for a variety of chronic mental and physical health problems, including anxiety disorders, depression, asthma, heart disease, certain cancers, and autoimmune and neurodegenerative disorders. Despite this fact, stress exposure and responses are rarely assessed in the primary care setting and infrequently targeted for disease prevention or treatment. Method: In this narrative review, we describe the primary reasons for this striking disjoint between the centrality of stress for promoting disease and how rarely it is assessed by summarizing the main conceptual, measurement, practical, and reimbursement issues that have made stress difficult to routinely measure in primary care. The following issues will be reviewed: a) assessment of stress in primary care, b) biobehavioral pathways linking stress and illness, c) the value of stress measurements for improving outcomes in primary care, d) barriers to measuring and managing stress, and e) key research questions relevant to stress assessment and intervention in primary care. Results: On the basis of our synthesis, we suggest several approaches that can be pursued to advance this work, including feasibility and acceptability studies, cost-benefit studies, and clinical improvement studies. Conclusions: Although stress is recognized as a key contributor to chronic disease risk and mortality, additional research is needed to determine how and when instruments for assessing life stress might be useful in the primary care setting, and how stress-related data could be integrated into disease prevention and treatment strategies to reduce chronic disease burden and improve human health and well-being.
- 24 January 2022
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 84 (3) , 267-275
Stress Measurement in Primary Care: Conceptual Issues, Barriers, Resources, and Recommendations for Study
Objective: Exposure to stressors in daily life and dysregulated stress responses are associated with increased risk for a variety of chronic mental and physical health problems, including anxiety disorders, depression, asthma, heart disease, certain cancers, and autoimmune and neurodegenerative disorders. Despite this fact, stress exposure and responses are rarely assessed in the primary care setting and infrequently targeted for disease prevention or treatment. Method: In this narrative review, we describe the primary reasons for this striking disjoint between the centrality of stress for promoting disease and how rarely it is assessed by summarizing the main conceptual, measurement, practical, and reimbursement issues that have made stress difficult to routinely measure in primary care. The following issues will be reviewed: a) assessment of stress in primary care, b) biobehavioral pathways linking stress and illness, c) the value of stress measurements for improving outcomes in primary care, d) barriers to measuring and managing stress, and e) key research questions relevant to stress assessment and intervention in primary care. Results: On the basis of our synthesis, we suggest several approaches that can be pursued to advance this work, including feasibility and acceptability studies, cost-benefit studies, and clinical improvement studies. Conclusions: Although stress is recognized as a key contributor to chronic disease risk and mortality, additional research is needed to determine how and when instruments for assessing life stress might be useful in the primary care setting, and how stress-related data could be integrated into disease prevention and treatment strategies to reduce chronic disease burden and improve human health and well-being.
- 23 July 2019
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 81 (7) , 568-569
Another Step Toward Clarifying the Benefits and Burdens of Selective Serotonin Reuptake Inhibitors
Selective serotonin reuptake inhibitors (SSRIs) have substantial beneficial effects for the treatment of major depressive mood disorders and other conditions but can also result in unwanted clinical outcomes. One of the reported disadvantages of SSRIs, based on cross-sectional studies, is their adverse effects on glycemic control. However, in this issue of Psychosomatic Medicine, Tharmaraja et al. report a meta-analysis of 16 randomized controlled trials, demonstrating beneficial effects of SSRIs on changes in glycemia. In this editorial, the advantages of meta-analysis in biobehavioral medicine are highlighted as well as the importance of the study designs (observational studies versus randomized controlled trials) on which the meta-analyses are based. This article concludes with an outline for future research directions in the area of SSRIs and glycemic control.
- 23 July 2019
- Published by Wolters Kluwer Health in Psychosomatic Medicine
- Vol. 81 (7) , 568-569
Another Step Toward Clarifying the Benefits and Burdens of Selective Serotonin Reuptake Inhibitors
Selective serotonin reuptake inhibitors (SSRIs) have substantial beneficial effects for the treatment of major depressive mood disorders and other conditions but can also result in unwanted clinical outcomes. One of the reported disadvantages of SSRIs, based on cross-sectional studies, is their adverse effects on glycemic control. However, in this issue of Psychosomatic Medicine, Tharmaraja et al. report a meta-analysis of 16 randomized controlled trials, demonstrating beneficial effects of SSRIs on changes in glycemia. In this editorial, the advantages of meta-analysis in biobehavioral medicine are highlighted as well as the importance of the study designs (observational studies versus randomized controlled trials) on which the meta-analyses are based. This article concludes with an outline for future research directions in the area of SSRIs and glycemic control.
- 24 April 2019
- Published by Elsevier in General Hospital Psychiatry
- Vol. 61, 90-95
Innovations for integrated care: The Association of Medicine and Psychiatry recognizes new models
- 24 April 2019
- Published by Elsevier in General Hospital Psychiatry
- Vol. 61, 90-95
Innovations for integrated care: The Association of Medicine and Psychiatry recognizes new models
- 1 March 2018
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 86, 12-20
Stress, autonomic imbalance, and the prediction of metabolic risk: A model and a proposal for research
- 1 March 2018
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 86, 12-20
Stress, autonomic imbalance, and the prediction of metabolic risk: A model and a proposal for research
- 26 February 2018
- Published by Wiley in Bipolar Disorders
- Vol. 20 (7) , 658-665
Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder
Objectives: The aims of the present study were to characterize cardiometabolic risk factors in a cohort of bipolar disorder patients with limited exposure to psychotropic medications, and to evaluate their associations with mood symptoms and omega‐3 polyunsaturated fatty acid (PUFA) blood levels.Methods: Cardiometabolic risk assessments were compared in individuals with bipolar I disorder experiencing a first manic or mixed episode or an early depressive episode (n=117) and healthy subjects (n=56). Patients were medication free at assessment and had no or limited exposure to mood‐stabilizer or antipsychotic medications prior to the current admission. Associations among cardiometabolic parameters and Clinical Global Impression—Severity scale (CGI‐S), manic (Young Mania Rating Scale [YMRS]), and depressive (Hamilton Depression Rating Scale [HDRS]) symptom ratings were evaluated within the bipolar group.Results: Following adjustment for demographic variables (i.e., age, gender, and parental education), significantly higher fasting triglyceride levels were observed in the bipolar group compared to the healthy group (121.7 mg/dL vs 87.0 mg/dL; P<.01). There were no clear trends for other metabolic indicators, including blood pressure, body mass index, and fasting glucose. Nineteen percent of the bipolar group and 6% of the healthy group met the criteria for metabolic syndrome (P=.23). The omega‐3 index was lower in the bipolar group (3.4% vs 3.9%; P<.01). Within the bipolar group, no associations were found between the cardiometabolic parameters and CGI‐S, YMRS, and HDRS symptom ratings.Conclusions: Recent‐onset medication‐free bipolar disorder is associated with higher triglyceride levels. These findings are suggestive of early metabolic dysregulation prior to long‐term psychotropic medication exposure. Lower omega‐3 PUFA levels in individuals with bipolar I disorder represent a potential therapeutic target for additional investigation.
- 26 February 2018
- Published by Wiley in Bipolar Disorders
- Vol. 20 (7) , 658-665
Cardiometabolic risks and omega‐3 index in recent‐onset bipolar I disorder
Objectives: The aims of the present study were to characterize cardiometabolic risk factors in a cohort of bipolar disorder patients with limited exposure to psychotropic medications, and to evaluate their associations with mood symptoms and omega‐3 polyunsaturated fatty acid (PUFA) blood levels.Methods: Cardiometabolic risk assessments were compared in individuals with bipolar I disorder experiencing a first manic or mixed episode or an early depressive episode (n=117) and healthy subjects (n=56). Patients were medication free at assessment and had no or limited exposure to mood‐stabilizer or antipsychotic medications prior to the current admission. Associations among cardiometabolic parameters and Clinical Global Impression—Severity scale (CGI‐S), manic (Young Mania Rating Scale [YMRS]), and depressive (Hamilton Depression Rating Scale [HDRS]) symptom ratings were evaluated within the bipolar group.Results: Following adjustment for demographic variables (i.e., age, gender, and parental education), significantly higher fasting triglyceride levels were observed in the bipolar group compared to the healthy group (121.7 mg/dL vs 87.0 mg/dL; P<.01). There were no clear trends for other metabolic indicators, including blood pressure, body mass index, and fasting glucose. Nineteen percent of the bipolar group and 6% of the healthy group met the criteria for metabolic syndrome (P=.23). The omega‐3 index was lower in the bipolar group (3.4% vs 3.9%; P<.01). Within the bipolar group, no associations were found between the cardiometabolic parameters and CGI‐S, YMRS, and HDRS symptom ratings.Conclusions: Recent‐onset medication‐free bipolar disorder is associated with higher triglyceride levels. These findings are suggestive of early metabolic dysregulation prior to long‐term psychotropic medication exposure. Lower omega‐3 PUFA levels in individuals with bipolar I disorder represent a potential therapeutic target for additional investigation.
- 8 June 2014
- Published by Springer Nature in Social Psychiatry and Psychiatric Epidemiology
- Vol. 49 (11) , 1805-1821
Prevalence rates for depression by industry: a claims database analysis
Purpose To estimate and interpret differences in depression prevalence rates among industries, using a large, group medical claims database. Methods Depression cases were identified by ICD-9 diagnosis code in a population of 214,413 individuals employed during 2002–2005 by employers based in western Pennsylvania. Data were provided by Highmark, Inc. (Pittsburgh and Camp Hill, PA). Rates were adjusted for age, gender, and employee share of health care costs. National industry measures of psychological distress, work stress, and physical activity at work were also compiled from other data sources. Results Rates for clinical depression in 55 industries ranged from 6.9 to 16.2 %, (population rate = 10.45 %). Industries with the highest rates tended to be those which, on the national level, require frequent or difficult interactions with the public or clients, and have high levels of stress and low levels of physical activity. Conclusions Additional research is needed to help identify industries with relatively high rates of depression in other regions and on the national level, and to determine whether these differences are due in part to specific work stress exposures and physical inactivity at work. Clinical significance Claims database analyses may provide a cost-effective way to identify priorities for depression treatment and prevention in the workplace.
- 8 June 2014
- Published by Springer Nature in Social Psychiatry and Psychiatric Epidemiology
- Vol. 49 (11) , 1805-1821
Prevalence rates for depression by industry: a claims database analysis
Purpose To estimate and interpret differences in depression prevalence rates among industries, using a large, group medical claims database. Methods Depression cases were identified by ICD-9 diagnosis code in a population of 214,413 individuals employed during 2002–2005 by employers based in western Pennsylvania. Data were provided by Highmark, Inc. (Pittsburgh and Camp Hill, PA). Rates were adjusted for age, gender, and employee share of health care costs. National industry measures of psychological distress, work stress, and physical activity at work were also compiled from other data sources. Results Rates for clinical depression in 55 industries ranged from 6.9 to 16.2 %, (population rate = 10.45 %). Industries with the highest rates tended to be those which, on the national level, require frequent or difficult interactions with the public or clients, and have high levels of stress and low levels of physical activity. Conclusions Additional research is needed to help identify industries with relatively high rates of depression in other regions and on the national level, and to determine whether these differences are due in part to specific work stress exposures and physical inactivity at work. Clinical significance Claims database analyses may provide a cost-effective way to identify priorities for depression treatment and prevention in the workplace.
- 14 January 2013
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 64 (1) , 385-392
Psychiatry's Integration with Medicine: The Role of DSM-5
Mental disorders represent a significant global burden whose effects are exacerbated by gaps in diagnosis and service provision. A substantial number of individuals seek services not through specialty psychiatric clinics but through primary care. Thus, the interface between psychiatry and the rest of medicine represents an appropriate area of focus in which to improve the detection and treatment of mental disorders. Development of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) can play a key role in this process. DSM-5 is expected to include specific revisions in diagnostic criteria, chapter organization, text structure, and classification approach that are designed to improve use of DSM by nonpsychiatrist physicians. Furthermore, revisions to DSM-5 will inform development of the primary care version of DSM-5. The goal is to publish a manual that enhances clinical utility in a manner that is concise and more amenable to use in primary care.
- 14 January 2013
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 64 (1) , 385-392
Psychiatry's Integration with Medicine: The Role of DSM-5
Mental disorders represent a significant global burden whose effects are exacerbated by gaps in diagnosis and service provision. A substantial number of individuals seek services not through specialty psychiatric clinics but through primary care. Thus, the interface between psychiatry and the rest of medicine represents an appropriate area of focus in which to improve the detection and treatment of mental disorders. Development of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) can play a key role in this process. DSM-5 is expected to include specific revisions in diagnostic criteria, chapter organization, text structure, and classification approach that are designed to improve use of DSM by nonpsychiatrist physicians. Furthermore, revisions to DSM-5 will inform development of the primary care version of DSM-5. The goal is to publish a manual that enhances clinical utility in a manner that is concise and more amenable to use in primary care.
- 1 March 2012
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 72 (3) , 175-179
Comparison of two depression measures for predicting stroke outcomes
- 1 March 2012
- Published by Elsevier in Journal of Psychosomatic Research
- Vol. 72 (3) , 175-179
Comparison of two depression measures for predicting stroke outcomes
- 1 January 2012
- Published by Springer Nature
- p. 9-24
Psychological Challenges of Coping with Coronary Artery Disease
- 1 January 2012
- Published by Springer Nature
- p. 9-24
Psychological Challenges of Coping with Coronary Artery Disease